Relief Therapeutics

221 articles about Relief Therapeutics

• Relief Therapeutics Announces Issuance of Shares from Authorized Capital

  12/13/2022

  RELIEF THERAPEUTICS Holding SA reported that its board of directors approved an increase of the Company's share capital from 4,616,334,617 to 5,616,334,617 shares through the issuance of 1,000,000,000 shares from its authorized capital.

• RELIEF THERAPEUTICS Holding SA and NRx Pharmaceuticals, Inc. Extend Their Stay of Pending Litigation to Provide Additional Time for The Parties to Finalize Their Settlement

  10/26/2022

  RELIEF THERAPEUTICS Holding SA today announced that they and NRx Pharmaceuticals, Inc. have agreed to extend the stay of their pending litigation until November 7, 2022 to allow time for the parties to finalize their tentative litigation settlement.

• Relief Therapeutics Files Amendment No. 2 to its Form F-6 Registration Statement with the U.S. Securities and Exchange Commission

  10/25/2022

  RELIEF THERAPEUTICS Holding SA, announced that it has filed Amendment No. 2 to its Form F-6 registration statement for depositary shares evidenced by American Depositary Receipt with the U.S. Securities and Exchange Commission.

• Relief Therapeutics Announces Promotion of Paolo Galfetti to Chief Operating Officer

  10/14/2022

  RELIEF THERAPEUTICS Holding SA, a Swiss, commercial-stage biopharmaceutical company identifying, developing and commercializing novel, patent protected products in selected specialty, rare and ultra-rare disease areas on a global basis, announced that Paolo Galfetti has been promoted to Chief Operating Officer, effective October 14, 2022.

• Relief Announces U.S. Launch of PKU GOLIKE

  10/10/2022

  RELIEF THERAPEUTICS Holding SA today announced the U.S. launch of PKU GOLIKE® - a next generation medical food product engineered with the patent protected, pharmaceutical grade Physiomimic™ technology for the dietary management of phenylketonuria (PKU).

• Relief Announces Exclusive Distributor for PKU GOLIKE in the U.S.

  10/6/2022

  RELIEF THERAPEUTICS Holding SA announced that it has hired a leading national health services company to serve as exclusive distributor of PKU GOLIKE ® in the U.S. PKU GOLIKE ® is a next generation medical food product engineered with the patent protected, pharmaceutical grade Physiomimic™ technology for the dietary management of phenylketonuria, and has been commercialized in the EU since 2019.

• Acer Therapeutics and Relief Therapeutics Announce Receipt of Notice of Allowance of US Patent Application Covering a Kit Comprising Phenylbutyrate and Sodium Benzoate

  10/3/2022

  Acer Therapeutics Inc. and RELIEF THERAPEUTICS Holding SA today announced that the US Patent and Trademark Office (USPTO) has issued a Notice of Allowance to Acer for US patent application No. 16/624,834 for claims related to a kit comprising a combination therapeutic product composed of sodium phenylbutyrate or glycerol phenylbutyrate and sodium benzoate.

• Relief Therapeutics Announces IRB Approval and Initiation of an Investigator Initiated Trial of Nexodyn for Epidermolysis Bullosa at Ann & Robert H. Lurie Children's Hospital of Chicago

  9/22/2022

  RELIEF THERAPEUTICS Holding SA announced that an Investigator Initiated Trial with Nexodyn for Epidermolysis Bullosa has received IRB approval and will shortly enroll participants at Ann & Robert H. Lurie Children's Hospital of Chicago with Professor Amy Paller, M.D., Chair, Department of Dermatology, Feinberg School of Medicine, Northwestern University, serving as Principal Investigator.

• Relief Reports Half-Year 2022 Results and Provides Corporate Update

  9/15/2022

  RELIEF THERAPEUTICS Holding SA reported its results for the half-year ended June 30, 2022 and provided a corporate update.

• Relief Therapeutics to Participate in the 22nd Annual Biotech in Europe Forum

  9/12/2022

  RELIEF THERAPEUTICS Holding SA announced that Jack Weinstein, Chief Financial Officer and Treasurer, will participate in a panel discussion and present a company overview during the 22 nd Annual Biotech in Europe Forum, being held September 21-22, 2022, in Basel, Switzerland.

• Relief Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

  9/7/2022

  RELIEF THERAPEUTICS Holding SA announced that Jack Weinstein, Chief Financial Officer and Treasurer, will present a company overview during the H.C. Wainwright 23rd Annual Global Investment Conference, being held September 12-14, 2022.

• Relief Therapeutics Files Registration Statement on form F-1 with the U.S. Securities and Exchange Commission

  8/24/2022

  RELIEF THERAPEUTICS Holding SA, announced today that it has filed a Registration Statement on Form F-1 under the Securities Act of 1933 with the U.S. Securities and Exchange Commission relating to a proposed offering of its ordinary shares in the form of American Depositary Shares.

• RELIEF THERAPEUTICS HOLDING SA AND NRX PHARMACEUTICALS, INC. ANNOUNCE TENTATIVE SETTLEMENT OF PENDING LITIGATION

  8/22/2022

  RELIEF THERAPEUTICS and NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) (" NRx "), today announced that they have agreed to a tentative settlement of their pending litigation.

• Relief Therapeutics Appoints David McCullough as Head of U.S. Market Access

  8/17/2022

  RELIEF THERAPEUTICS Holding SA, a biopharmaceutical company seeking to provide patients therapeutic benefit from serious diseases with high unmet need, announced the appointment of David McCullough as Senior Director and Head of U.S. Market Access, effective August 22 nd.

• Relief Therapeutics and Acer Therapeutics Announce that the European Commission Has Granted Orphan Drug Designation for ACER-001 in Maple Syrup Urine Disease

  8/12/2022

  RELIEF THERAPEUTICS Holding SA and Acer Therapeutics Inc. (Nasdaq: ACER) (Acer), today announced that the European Commission has granted orphan medicinal product designation in the EU to ACER-001 (sodium phenylbutyrate) for the potential treatment of patients with Maple Syrup Urine Disease (MSUD).

• Relief Therapeutics Announces Promising Initial Stability Data on a New Formulation of RLF-100(R) (Aviptadil)

  8/3/2022

  RELIEF THERAPEUTICS Holding SA, a biopharmaceutical company seeking to provide patients therapeutic benefit from serious diseases with high unmet need, announced promising three-month stability data on a new formulation of RLF-100®.

• Acer Therapeutics and Relief Therapeutics Announce ACER-001 IND Submission for the Treatment of Maple Syrup Urine Disease

  7/28/2022

  Acer Therapeutics Inc. and RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief), today announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to evaluate the efficacy and safety of ACER-001.

• Relief Therapeutics Announces Effectiveness of Registration Statement on Form 20-F

  7/21/2022

  RELIEF THERAPEUTICS Holding SA announced that the U.S. Securities and Exchange Commission has declared effective its Registration Statement on Form 20-F.

• Relief Therapeutics Announces that its Collaboration Partner has Resubmitted the ACER-001 (Sodium Phenylbutyrate) New Drug Application (NDA) to the FDA for the Treatment of Urea Cycle Disorders (UCDs)

  7/18/2022

  RELIEF THERAPEUTICS Holding SA, announced that its collaboration partner, ACER Therapeutics, Inc., for ACER-001 for oral suspension for the treatment of patients with urea cycle disorders, has resubmitted its New Drug Application for ACER-001 to the U.S. Food and Drug Administration.

• Relief Therapeutics Appoints Serene Forte, Ph.D., MPH, as Senior Vice President, Head of Genetic Medicine

  7/18/2022

  RELIEF THERAPEUTICS Holding SA, a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, announced the appointment of Serene Forte, Ph.D., MPH, as Senior Vice President, Head of Genetic Medicine, effective July 18, 2022.